Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Phase 1
Completed
- Conditions
- Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasStage IV Pancreatic CancerRecurrent Pancreatic CancerUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Other: laboratory biomarker analysisOther: pharmacogenomic studiesOther: pharmacological study
- First Posted Date
- 2009-09-22
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT00981162
- Locations
- 🇺🇸
University of Colorado at Denver Health Sciences Center, Aurora, Colorado, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate CancerCancer of ProstateProstate NeoplasmsNeoplasms, ProstaticProstatic CancerCancer of the ProstateNeoplasms, Prostate
- Interventions
- Biological: androgen ablation (AA)Biological: DC1 vaccine
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 13
- Registration Number
- NCT00970203
- Locations
- 🇺🇸
University of Pittsburgh Cancer institute, Pittsburgh, Pennsylvania, United States
Acceptability of Less Harmful Alternatives to Cigarettes
Not Applicable
Completed
- Conditions
- Head and Neck CancerLiver CancerPancreatic CancerKidney CancerLeukemiaTobacco Use DisorderBladder CancerEsophageal CancerCervical CancerGastric Cancer
- Interventions
- Behavioral: telephone-based interventionOther: informational interventionOther: internet-based interventionOther: questionnaire administration
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 67
- Registration Number
- NCT00957424
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
Phase 2
Completed
- Conditions
- Adenocarcinoma of the ColonAdenocarcinoma of the RectumRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal Cancer
- Interventions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2014-06-23
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 58
- Registration Number
- NCT00942266
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
Not Applicable
Terminated
- Conditions
- Head and Neck Cancer
- Interventions
- Biological: cetuximabRadiation: stereotactic body radiation therapy
- First Posted Date
- 2009-05-01
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00891904
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation
Not Applicable
Completed
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Dietary Supplement: CholecalciferolOther: Laboratory Biomarker AnalysisOther: Patient ObservationDrug: Placebo AdministrationOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 132
- Registration Number
- NCT00887432
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
Not Applicable
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Angioimmunoblastic T-cell LymphomaChildhood Myelodysplastic SyndromesAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Diffuse Large Cell LymphomaChildhood Nasal Type Extranodal NK/T-cell Lymphoma
- Interventions
- Radiation: total-body irradiationProcedure: allogeneic hematopoietic stem cell transplantationBiological: anti-thymocyte globulin
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 62
- Registration Number
- NCT00856388
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
Phase 2
Terminated
- Conditions
- Lymphoma
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00851552
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
Not Applicable
Completed
- Conditions
- Kidney Cancer
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00849186
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- Interventions
- Radiation: Arm 1 stereotactic body radiation therapyRadiation: Arm II stereotactic body radiation therapy
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2021-06-15
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 98
- Registration Number
- NCT00843726
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸SUNY Upstate Medical University, Syracuse, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States